Afatinib D6 is the hexa-deuterated form of Afatinib (BIBW-2992; Gilotrif), which is an orally bioavailable dual (EGFR/ErbB) receptor
tyrosine kinase (RTK) inhibitor approved by FDA as an anticancer drug to treat non-small cell lung carcinoma (NSCLC).
纯度:≥98%
CAS:1313874-96-2